WHO Endorses GLP-1 Analogs for Obesity Management
Geneva. The World Health Organization (WHO) issued a recommendation this Monday in favor of using three analogue drugs of the GLP-1,originally designed to treat type 2 diabetes,in patients with obesity – a condition affecting one billion people,a number projected to double within five years.
Thes medications – semaglutide, liraglutide, and tirzepatide – mimic intestinal hormones. They reduce appetite, slow gastric emptying (promoting a feeling of fullness), and improve glucose regulation.Though,their use for weight loss has been a subject of debate.
Concerns include the potential for shortages of these drugs for diabetic patients due to widespread use for weight loss.An ethical discussion has also emerged regarding their use for cosmetic purposes and their high cost for public health systems.
Read also Mexico, with the lowest life expectancy in the OECD; has the highest rates of obesity and diabetes
These therapies have also faced criticism because individuals often regain much of the lost weight when medication is discontinued, potentially making them a treatment for chronic use.
Despite these concerns, the obesity crisis represents a significant health challenge, and the WHO recognizes the need for effective interventions.
Key Takeaways
- The WHO now recommends certain GLP-1 analog drugs for obesity treatment.
- These drugs work by mimicking intestinal hormones, reducing appetite, and improving glucose control.
- Concerns exist regarding drug shortages for diabetic patients, ethical considerations, and the potential for weight regain upon stopping medication.
- Obesity is a growing global health crisis,impacting one billion people worldwide.
Frequently Asked Questions (FAQ)
- What are GLP-1 analogs?
- GLP-1 analogs are medications that mimic the effects of a natural hormone called glucagon-like peptide-1. They are originally developed to treat type 2 diabetes but have shown effectiveness in weight management.
- Are these drugs safe?
- These drugs have undergone clinical trials and are generally considered safe when prescribed and monitored by a healthcare professional. Though, like all medications, they can have side effects.
- Will I regain weight if I stop taking the medication?
- There is a tendency to regain weight after stopping these medications. Long-term lifestyle changes, including diet and exercise, are crucial for maintaining weight loss.
- Are these drugs affordable?
- The cost of these medications can be high, posing a barrier to access for some individuals. Discussions are ongoing regarding affordability and equitable access.
Related reading
- UCLA Scientists Engineer Cord Blood T Cells to Target Hidden Solid Tumors
- Flu and COVID-19 Twindemic Ahead of Chuseok: Prevention Tips for High-Risk Groups
- Why Placebos Still Work Even When Patients Know They're Fake (daybreakwire.com)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)